Next-Generation Biopharma Products That Are About to Hit the Market
Biggest Biopharma Products Set to Launch
Roche's mosunetuzumab (GO2976): This antibody-drug conjugate (ADC) is being developed for the treatment of relapsed or refractory follicular lymphoma (FL). It is expected to be released in 2023. Mosunetuzumab is a first-in-class ADC that targets CD20, a protein found on the surface of B cells. The ADC is designed to deliver a toxic payload to cancer cells that express CD20. In clinical trials, mosunetuzumab has shown promising results in patients with FL.
Novartis's glypivan (NN901): This oral GLP-1 receptor agonist is being developed for the treatment of type 2 diabetes. It is expected to be released in 2023. Glypivan is a once-daily pill that helps to control blood sugar levels in people with type 2 diabetes. It works by stimulating the production of insulin and suppressing the production of glucagon. In clinical trials, glypivan has shown to be effective in lowering blood sugar levels and improving glycemic control.
Spark Therapeutics's voretigene neparvovec-rzyl (Luxturna): This gene therapy is being developed for the treatment of inherited retinal diseases. It is expected to be released in 2023. Voretigene neparvovec-rzyl is a gene therapy that is designed to replace a defective gene that causes inherited retinal diseases. The gene therapy is injected into the eye, and it works by delivering a healthy copy of the gene to retinal cells. In clinical trials, voretigene neparvovec-rzyl has shown to be effective in improving vision in people with inherited retinal diseases.
Sanofi's tolebrutinib (SAR402168): This Bruton's tyrosine kinase (BTK) inhibitor is being developed for the treatment of chronic lymphocytic leukemia (CLL). It is expected to be released in 2023.
Tolebrutinib is a BTK inhibitor that works by blocking the activity of BTK, an enzyme that is involved in the growth and survival of B cells. In clinical trials, tolebrutinib has shown to be effective in treating CLL.
Final Thoughts
The next generation of biopharma products is poised to make a significant impact on the way we treat disease. These products offer new hope for patients with a variety of diseases, and they have the potential to revolutionize the way we treat disease. It will be exciting to see how these products develop and how they impact the lives of patients in the years to come.
